Amgen vs. Novo Nordisk: Which Healthcare Giant's Stock Is a Better Buy in 2026?

Key PointsAmgen maintains a robust presence in oncology and rare diseases with a 9.9% revenue growth rate in FY 2025.

阅读完整 Veytics 简报

我们公开展示核心要点。创建免费账户后可继续阅读全文、保存、讨论，并结合市场和 OSINT 背景分析。